Stock Research for ADXS


Featured Broker: Ally Invest

Get the due diligence for another stock.


ADXS Stock Chart & Research Data

The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ADXS Due diligence Resources & Stock Charts

The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADXS Detailed Price Forecast - CNN Money CNN View ADXS Detailed Summary - Google Finance
Yahoo View ADXS Detailed Summary - Yahoo! Finance Zacks View ADXS Stock Research & Analysis -

Stock Analysis

TradeIdeas View ADXS Trends & Analysis - Trade-Ideas Barrons View ADXS Major Holders - Barrons
NASDAQ View ADXS Call Transcripts - NASDAQ Seeking View ADXS Breaking News & Analysis - Seeking Alpha
Spotlight View ADXS Annual Report - OTC Report View ADXS OTC Short Report -
TradeKing View ADXS Fundamentals - TradeKing Charts View ADXS SEC Filings - Bar Chart
WSJ View Historical Prices for ADXS - The WSJ Morningstar View Performance/Total Return for ADXS - Morningstar
MarketWatch View the Analyst Estimates for ADXS - MarketWatch CNBC View the Earnings History for ADXS - CNBC
StockMarketWatch View the ADXS Earnings - StockMarketWatch MacroAxis View ADXS Buy or Sell Recommendations - MacroAxis
Bullish View the ADXS Bullish Patterns - American Bulls Short Pains View ADXS Short Pain Metrics -

Social Media Mentions

StockTwits View ADXS Stock Mentions - StockTwits PennyStocks View ADXS Stock Mentions - PennyStockTweets
Twitter View ADXS Stock Mentions - Twitter Invest Hub View ADXS Investment Forum News - Investor Hub
Yahoo View ADXS Stock Mentions - Yahoo! Message Board Seeking Alpha View ADXS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ADXS - Insider Cow View Insider Transactions for ADXS - Insider Cow
CNBC View ADXS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADXS - OTC Markets
Yahoo View Insider Transactions for ADXS - Yahoo! Finance NASDAQ View Institutional Holdings for ADXS - NASDAQ

Stock Charts

FinViz View ADXS Stock Insight & Charts - StockCharts View ADXS Investment Charts -
BarChart View ADXS Stock Overview & Charts - BarChart Trading View View ADXS User Generated Charts - Trading View

Latest Financial News for ADXS

Biotech Companies with Great Futures
Posted on Monday July 16, 2018 is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential. HENDERSON, NV / ACCESSWIRE ...

Why Advaxis Stock Is Soaring Today
Posted on Friday July 13, 2018

Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).

Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug
Posted on Friday July 13, 2018

Shares of the late-stage immuno-oncology company Advaxis, Inc. (NASDAQ: ADXS) are adding about one-fifth of their value in the wake of a positive regulatory announcement. The FDA lifted the clinical hold it previously placed on the company's investigational new drug application for its axalimogene filolisbac in combination with durvalumab to treat patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer, according to Advaxis. The FDA imposed a clinical hold March 9 following a safety report of a patient death that occurred Feb. 27 after dosing.

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial
Posted on Friday July 13, 2018

Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

Enter a stock symbol to view the stock details.